Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NOR-101
- Development stage
- Phase 1
- Lead developer
- Central Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
NOR-101 is a half-life extended bispecific antibody designed to simultaneously target interleukin-13 (IL-13) and interleukin-18 (IL-18). Developed by North Immunology, the drug candidate is engineered to inhibit both type 2 and non-type 2 inflammatory pathways that drive atopic dermatitis and other immune-mediated diseases. By neutralizing the downstream effector cytokine IL-13 and the upstream innate alarmin IL-18, NOR-101 aims to provide deeper and more durable therapeutic responses compared to monospecific IL-13 therapies. Preclinical studies in non-human primates have demonstrated promising bioavailability and an extended half-life of approximately 42 days.
02
Targets
IL-13 (Interleukin-13)IL18 (Interleukin-18)
Beyond the preview
Go deeper on NOR-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NOR-101.